AMJEVITA Canadian Trademark Information

On Friday, July 29, 2016, a canadian trademark registration was filed for AMJEVITA by Amgen Inc. *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1793767. The current status of this trademark filing is Registration published. The AMJEVITA trademark is filed in the description of Pharmaceutical preparations, including biosimilars; pharmaceutical preparations and substances used for the treatment of bone, joint, intestine, colon, skin, lung, eye, bladder, blood cells, and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune and immune system, inflammatory, inflammatory bowel, gastrointestinal, musculoskeletal, dermatological, pulmonary, respiratory, oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, crohn's disease, ulcerative colitis, intestinal behçet's disease, chronic pouchitis, small bowel lesions, hermansky-pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, pyoderma gangrenosum, giant cell arteritis, netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthma. , Biosimilars, pharmaceutical preparations and substances used for the treatment of bone, joint, intestine, colon, skin, lung, eye, bladder, blood cells, and blood vessel diseases and disorders; biosimilars, pharmaceutical preparations and substances for the treatment of autoimmune and immune system, inflammatory, inflammatory bowel, gastrointestinal, musculoskeletal, dermatological, pulmonary, respiratory, oncological, and ophthalmic diseases and disorders; biosimilars, pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, crohn's disease, ulcerative colitis, intestinal behçet's disease, chronic pouchitis, small bowel lesions, hermansky-pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, pyoderma gangrenosum, giant cell arteritis, netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthma. , Biosimilars, pharmaceutical preparations and substances used for the treatment of bone, joint, intestine, colon, skin, lung, eye, bladder, blood cells, and blood vessel diseases and disorders; biosimilars, pharmaceutical preparations and substances for the treatment of autoimmune and immune system, inflammatory, inflammatory bowel, gastrointestinal, musculoskeletal, dermatological, pulmonary, respiratory, oncological, and ophthalmic diseases and disorders; biosimilars, pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, crohn's disease, ulcerative colitis, intestinal behçet's disease, chronic pouchitis, small bowel lesions, hermansky-pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, pyoderma gangrenosum, giant cell arteritis, netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthma. , Biosimilars, pharmaceutical preparations and substances used for the treatment of bone, joint, intestine, colon, skin, lung, eye, bladder, blood cells, and blood vessel diseases and disorders; biosimilars, pharmaceutical preparations and substances for the treatment of autoimmune and immune system, inflammatory, inflammatory bowel, gastrointestinal, musculoskeletal, dermatological, pulmonary, respiratory, oncological, and ophthalmic diseases and disorders; biosimilars, pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, crohn's disease, ulcerative colitis, intestinal behçet's disease, chronic pouchitis, small bowel lesions, hermansky-pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, pyoderma gangrenosum, giant cell arteritis, netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthma. .